Burden of Illness in Geographic Atrophy: A Study of Vision-Related Quality of Life and Health Care Resource Use
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Purpose: To gain comprehensive information on the burden of illness due to geographic atrophy (GA). Methods: This cross-sectional study with a retrospective chart review involved patients aged ≥70 years with physician-confirmed bilateral symptomatic GA due to age-related macular degeneration (GA group), as well as patients of similar age with no ophthalmic condition that in the opinion of the investigator affected visual function (non-GA group). Data relating to patients’ current disease status and sociodemographics were self-reported on patient questionnaires at study entry and extracted from patient charts. Historical data on health care resource utilization (HCRU) were also collected via patient questionnaires and retrospective chart review (GA group only). Overall vision-related functioning and quality of life (QoL) were compared between the GA and non-GA groups using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) composite and subscales, and change in vision over the past year was assessed using the Global Rating of Change Scale. Results: Vision-related functioning and QoL were poorer in patients with vs without GA (n=137 vs 52), as demonstrated by significantly lower NEI-VFQ-25 composite score (mean, 53.1 vs 84.5 points, respectively; P <0.001), as well as lower subscale scores for near activities, distance activities, dependency, driving, social functioning, mental health, role difficulties, color vision, and peripheral vision. Substantially more patients with GA than without GA reported worsening in vision over the past year (82% vs 25%, respectively; odds ratio, 13.55; P <0.001). In the GA group, associated mean annual costs for direct ophthalmological resource use per patient amounted to €1772 (mostly for tests/procedures), and for indirect ophthalmological resource use, €410 (mostly for general practitioner visits). Conclusion: Patients with GA experience a poorer level of vision-related function and QoL than their peers, especially in relation to driving. GA is also associated with notable HCRU/associated costs, mostly direct costs attributed to diagnostic tests/procedures. Keywords: burden of illness, geographic atrophy, vision-related quality of life, health care resource utilization, visual function, health care costs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Direct medical costs were reported in all studies [44, 46, 47] and were expressed as mean annual costs per patient in two [44, 46], ranging from $496 to $2,633.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Direct non-medical costs related to formal care and assistive technologies were estimated at $620 per patient per year in one multi-country study led by Patel et al. [46].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given the absence of treatment options for dry AMD at the time of the studies’ publication, no treatment cost related to the condition was considered in any of the three studies.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three studies [44, 46, 47] estimated costs associated with dry AMD and more specifically geographic atrophy, the advanced form of dry AMD (Fig. 4 and Supplementary Table 4).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While ophthalmological care was accounted for in all studies, costs pertaining to care for depression and falls was explicitly considered in one multi-country study [46].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“The incidence of GA increases exponentially with age, and as the population ages, the prevalence of the disease is expected to rise.(4,6) GA comprises a spectrum of heterogeneous, phenotypically distinct forms, in which visual function is determined by the remaining area in relation to the fovea.”
BackgroundJaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Retinal nerve fiber layer analysis in the diagnosis of glaucoma
Zangwill, L. M., & Bowd, C. (2006) · Current Opinion in Ophthalmology · doi:10.1097/01.icu.0000193079.55240.18 · Cited by 595 · cited 2×
“Advanced AMD has been estimated to cause a 63% decrease in the average patient’s quality of life (QoL), which is comparable to the effect of end-stage prostate cancer or catastrophic stroke on QoL.13 However, there is sparse knowledge of the impact of GA on patients’ QoL, as well as on society and health care resource…”
MethodInfluentialThe Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Fleckenstein, M., Mitchell, P., Freund, K. B., Sadda, S., Holz, F. G., Brittain, C., Henry, E. C., & Ferrara, D. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.038 · Cited by 561
Holz, F. G., Strauss, E. C., Schmitz-Valckenberg, S., & van Lookeren Campagne, M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.023 · Cited by 402
Rudnicka, A. R., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A., & Owen, C. G. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.09.027 · Cited by 394
Sunness, J. S., Gonzalez-Baron, J., Applegate, C. A., Bressler, N. M., Tian, Y., Hawkins, B., Barron, Y., & Bergman, A. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90340-8 · Cited by 348 · cited 10×
“Differences in Vision-Related Functioning and QoL Between the GA and Non-GA Groups Patients with GA had poorer vision-related functioning and QoL than those without GA. Patients in the GA group had a significantly lower mean (SD) NEI-VFQ-25 composite score than those in the non-GA group (53.1 [19.05] vs 84.5 [6.55] po…”
ResultInfluentialKaiser, P. K. (2009) · PubMed Central · Cited by 315
Sunness, J. S., Rubin, G. S., Applegate, C. A., Bressler, N. M., Marsh, M. J., Hawkins, B. S., & Haselwood, D. (1997) · Ophthalmology · doi:10.1016/s0161-6420(97)30079-7 · Cited by 309 · cited 11×
“Differences in Vision-Related Functioning and QoL Between the GA and Non-GA Groups Patients with GA had poorer vision-related functioning and QoL than those without GA. Patients in the GA group had a significantly lower mean (SD) NEI-VFQ-25 composite score than those in the non-GA group (53.1 [19.05] vs 84.5 [6.55] po…”
BackgroundResultInfluentialChange in Area of Geographic Atrophy in the Age-Related Eye Disease Study: AREDS Report Number 26
(2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.198 · Cited by 276
Traverso, C. E. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.067355 · Cited by 273 · cited 1×
“costs of up to $3260 (€2882) per patient were reported over 2 years for patients with exfoliation glaucoma syndrome in the United States, or €969 per year per patient in European patients with stage 4 glaucoma.(40,41) Clegg et al also reviewed the annual direct costs of managing a cohort of 1000 patients with dry eye…”
BackgroundBoyer, D. S., Schmidt-Erfurth, U., van Lookeren Campagne, M., Henry, E. C., & Brittain, C. (2017) · Retina · doi:10.1097/iae.0000000000001392 · Cited by 258
Bindewald, A. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.057794 · Cited by 186
Yaspan, B. L., Williams, D. F., Holz, F. G., Regillo, C. D., Li, Z., Dressen, A., van Lookeren Campagne, M., Le, K. N., Graham, R. R., Beres, T., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1443 · Cited by 186 · cited 4×
“The poorer function seen in patients in our study is despite the greater GA severity in the Mahalo population; patients recruited into Mahalo had to have a GA lesion size of ~1–7 DA at baseline, whereas 21% of worse-seeing eyes in our study had GA lesions of <1 DA.(27) These differences may be in part due to differenc…”
ResultInfluentialRudnicka, A. R., Kapetanakis, V. V., Jarrar, Z., Wathern, A. K., Wormald, R., Fletcher, A. E., Cook, D. G., & Owen, C. G. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.003 · Cited by 181 · cited 1×
“Despite the converging recruiting paths, patients with GA tended to be older than those in the non-GA group, which reflects the increasing GA incidence with advancing age.(35) The patients with GA also had a broad distribution of lesion sizes, mostly estimated by FAF, OCT, or color fundus photography.”
BackgroundSun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3225 · Cited by 170 · cited 5×
“America.2 GA has also been associated with more cases of legal blindness (severe sight loss/registered blind) in England and Wales than other forms of AMD.5 The incidence of GA increases exponentially with age, and as the population ages, the prevalence of the disease is expected to rise.4,6 GA comprises a spectrum of…”
BackgroundResultInfluentialLotery, A., Xu, X., Zlatava, G., & Loftus, J. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.116939 · Cited by 124 · cited 1×
“The annualized average total cost (direct and indirect ophthalmic HCRU) was €2006 per patient with GA, which is similar to direct vision-related medical and non–visionrelated medical costs (including fall-related and other injuries, depression/anxiety) reported for patients with neovascular AMD in a UK cohort study in…”
ResultClegg, J. P., Guest, J. F., Lehmann, A., & Smith, A. F. (2006) · Ophthalmic Epidemiology · doi:10.1080/09286580600801044 · Cited by 122
The burden of neovascular age-related macular degeneration: a patient’s perspective
Spooner, K., Mhlanga, C., Hong, T., Broadhead, G., & Chang, A. (2018) · Clinical Ophthalmology · doi:10.2147/opth.s185052 · Cited by 121 · cited 1×
“The NEI-VFQ-25 scores reported herein were also lower (ie, poorer) than previously reported in patients with neovascular AMD in two ranibizumab clinical trials (MARINA and ANCHOR) at baseline, as well as in a cross-sectional, non-interventional study in patients undergoing anti–vascular endothelial growth factor thera…”
ResultChakravarthy, U., Bailey, C. C., Johnston, R. L., McKibbin, M., Khan, R. S., Mahmood, S., Downey, L., Dhingra, N., Brand, C., Brittain, C. J., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.036 · Cited by 118 · cited 12×
“Differences in Vision-Related Functioning and QoL Between the GA and Non-GA Groups Patients with GA had poorer vision-related functioning and QoL than those without GA. Patients in the GA group had a significantly lower mean (SD) NEI-VFQ-25 composite score than those in the non-GA group (53.1 [19.05] vs 84.5 [6.55] po…”
BackgroundResultInfluentialSelf-citationOrr, P. R., Rentz, A. M., Margolis, M. K., Revicki, D. A., Dolan, C., Colman, S. S., Fine, J. T., & Bressler, N. M. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5645 · Cited by 116
The burden of age-related macular degeneration: a value-based analysis
Brown, M. M., Brown, G. C., Sharma, S., Stein, J. D., Roth, Z. B., Campanella, J., & Beauchamp, G. R. (2006) · Current Opinion in Ophthalmology · doi:10.1097/01.icu.0001276628.01684.a6 · Cited by 115
Prevalence and causes of registered blindness in the largest federal state of Germany
Finger, R. P., Fimmers, R., Holz, F. G., & Scholl, H. P. N. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.194712 · Cited by 95
Guidelines for good pharmacoepidemiology practices (GPP)
Epstein, M. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1082 · Cited by 90
Roh, M., Selivanova, A., Shin, H. J., Miller, J. W., & Jackson, M. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196481 · Cited by 83 · cited 1×
“While it is accepted that GA has a negative impact on patients’ QoL, society, and the health care system,(12,14) there is limited published evidence specific to GA to confirm this.(16,17) This may be due in part to the fact that GAwas only granted a code in the US-specific International Classification of Diseases, 10t…”
BackgroundFundus Autofluorescence in Age‐related Macular Degeneration
Ly, A., Nivison‐Smith, L., Assaad, N. N., & Kalloniatis, M. (2016) · Optometry and Vision Science · doi:10.1097/opx.0000000000000997 · Cited by 67
Stevenson, M. R., Hart, P. M., Montgomery, A.-M., McCulloch, D., & Chakravarthy, U. (2004) · British Journal of Ophthalmology · doi:10.1136/bjo.2003.032383 · Cited by 66 · cited 1×
“While it is accepted that GA has a negative impact on patients’ QoL, society, and the health care system,(12,14) there is limited published evidence specific to GA to confirm this.(16,17) This may be due in part to the fact that GAwas only granted a code in the US-specific International Classification of Diseases, 10t…”
BackgroundDivergence in the Lived Experience of People with Macular Degeneration
McCloud, C., Khadka, J., Gilhotra, J. S., & Pesudovs, K. (2014) · Optometry and Vision Science · doi:10.1097/opx.0000000000000320 · Cited by 59 · cited 1×
“Worsening vision as well as the fear of deterioration can place a significant psychological burden on patients with GA, resulting in increased road traffic insecurity, isolation, fears about the future, and a profound loss for the daily activities that are no longer possible.(33) In the current study, although half of…”
BackgroundSOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES
Brown, M. M., Brown, G. C., Lieske, H. B., Tran, I., Turpcu, A., & Colman, S. (2016) · Retina · doi:10.1097/iae.0000000000000717 · Cited by 59
Sivaprasad, S., Tschosik, E., Kapre, A., Varma, R., Bressler, N. M., Kimel, M., Dolan, C., & Silverman, D. G. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.03.006 · Cited by 56 · cited 5×
“The primary objective was to compare the overall vision-related functioning and QoL in the GA group with that in a non-GA group of similar age using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25), which has been validated for use in patients with GA.(20) Secondary objectives were (1) to asses…”
BackgroundMethodResultInfluentialSelf-citationTaylor, D. J., Jones, L., Binns, A. M., & Crabb, D. P. (2019) · Eye · doi:10.1038/s41433-019-0445-8 · Cited by 50
The economic and humanistic burden of patients in receipt of current available therapies for nAMD
Jaffe, D. H., Chan, W. W., Bezlyak, V., & Skelly, A. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0058 · Cited by 40 · cited 2×
“This difference is most likely due to the lack of an available treatment in the patients with GA, in line with the increased demand for health care services observed in patients with neovascular AMD and receiving treatment compared with non–neovascular AMD controls, especially within Europe.(39) In our study, 24/46 pa…”
ResultLiving with Geographic Atrophy: An Ethnographic Study
Sivaprasad, S., Tschosik, E., Guymer, R. H., Kapre, A., Suñer, I. J., Joussen, A. M., Lanzetta, P., & Ferrara, D. (2019) · Ophthalmology and Therapy · doi:10.1007/s40123-019-0160-3 · Cited by 38 · cited 10×
“Differences in Vision-Related Functioning and QoL Between the GA and Non-GA Groups Patients with GA had poorer vision-related functioning and QoL than those without GA. Patients in the GA group had a significantly lower mean (SD) NEI-VFQ-25 composite score than those in the non-GA group (53.1 [19.05] vs 84.5 [6.55] po…”
ResultInfluentialSelf-citationRees, A., Zekite, A., Bunce, C., & Patel, P. J. (2014) · Eye · doi:10.1038/eye.2014.103 · Cited by 34
Self-citationRicci, E., Garattini, L., Castelnuovo, E., Lanzetta, P., Viscarra, C., & Parazzini, F. (2004) · The European Journal of Health Economics · doi:10.1007/s10198-003-0198-x · Cited by 19
The Cost of Blindness in the Republic of Ireland 2010–2020
Green, D., Ducorroy, G., McElnea, E. M., Naughton, A., Skelly, A., O’Neill, C., Kenny, D., & Keegan, D. (2016) · Journal of Ophthalmology · doi:10.1155/2016/4691276 · Cited by 15
Rathi, S., Andrews, C., Greenfield, D. S., & Stein, J. D. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.12.024 · Cited by 10 · cited 1×
“costs of up to $3260 (€2882) per patient were reported over 2 years for patients with exfoliation glaucoma syndrome in the United States, or €969 per year per patient in European patients with stage 4 glaucoma.(40,41) Clegg et al also reviewed the annual direct costs of managing a cohort of 1000 patients with dry eye…”
Background
Research works printed but not linked: 1
- [14]Orr S. Disease burden associated with geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016; 57(12): 21.
Cited by
Heier, J. S., Lad, E. M., Holz, F. G., Rosenfeld, P. J., Guymer, R. H., Boyer, D., Grossi, F., Baumal, C. R., Korobelnik, J.-F., Slakter, J. S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01520-9 · Cited by 520
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
Bakri, S. J., Bektas, M., Sharp, D. A., Luo, R. T., Sarda, S. P., & Khan, S. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5-a.s2 · Cited by 73
Rowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 53
“…irreversible visual impairment in individuals aged 60 The burden of illness associated with geographic atrophy is considerable, greatly diminishing the quality of life for both patients and their caregivers [55,56]. years or older, with approximately 5 million people affected by GA globally [9,54].”
BackgroundEconomic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US
Paudel, N., Brady, L., Stratieva, P., Galvin, O., Lui, B., Brande, I. V. D., Malkowski, J., Rebeira, M., MacAllister, S., O’Riordan, T., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.4401 · Cited by 44
Wykoff, C. C., Hershberger, V. S., Eichenbaum, D. A., Henry, E. C., Younis, H. S., Chandra, P., Yuan, N., Solloway, M. J., & DePaoli, A. M. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.08.018 · Cited by 31
Metadata
- Authors
- Patel, P. J., Ziemssen, F., Ng, E., Muthutantri, A., Silverman, D., Tschosik, E. A., & Cantrell, R. A.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Tübingen (DE)
- Waterford Institute of Technology (IE)
- IQVIA (United Kingdom) (GB)
- Roche (United Kingdom) (GB)
- Roche (United States) (US)
- Corresponding author
- Silverman, David
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- Volume 14
- Pages
- 15-28
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC6955611
- OpenAlex
- W2999121317
- Cited by
- 61
- References
- 38
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 16 · 2023: 9 · 2022: 4 · 2021: 5
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- F. Hoffmann-La Roche
- Nottingham University Hospitals NHS Trust
- University of Nottingham
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- geographic atrophy, age-related macular degeneration, disease burden, vision-related quality of life, healthcare resource utilization, health care costs, visual function, driving impairment, NEI VFQ-25, older adults
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.